Multiple Sclerosis (MS) is a chronic, heterogeneous, autoimmune disease of the central nervous system (CNS), affecting more than 400,000 people in the US and 2.5 million people globally. Two subtypes, Clinically Isolated Syndrome (CIS) and Relapsing-Remitting Multiple Sclerosis (RRMS), represent the disease absent progression, while Primary Progressive (PPMS) and Secondary Progressive (SPMS) represent patients with progressive disease from the start or after RRMS, respectively. Neuroinflammation leading to multifocal lesion formation, demyelination, axonal damage and consequent neurodegeneration are hallmarks of the disease. Morbidity is high with 80% of patients developing severe disability, and life expectancy reduced by 10 years. While current treatments can lessen the severity of symptoms or slow disease progressions, there is no cure, and many patients (especially in progressive forms of the disease) remain refractory to the standard of care.
Saud Sadiq, MD
Dr. Saud Sadiq is the director of the Tisch MS Research Center of New York. A native of Kenya, is a board-certified neurologist who completed medical school at the University of Nairobi and residency training in Internal Medicine in Kenya and in England His research interests are focused on MS and include investigating the intrathecal oligoclonal B-cell response; exploring the mechanisms of disease progression, biomarker development, and applying stem cell biology to clinical use. Clinically, Dr. Sadiq is an internationally acknowledged expert in MS, receiving numerous awards for his research and clinical activities. He has been an invited guest speaker nationally and internationally at numerous conferences and has more than 100 publications. He is among a select few MS specialists who has a full time clinical practice and is able to combine it with directing a productive laboratory-based research program.
Jamie Wong, PhD
Minnetronix is a registered trademark, and Neurapheresis is a trademark of Minnetronix, Inc.
©Minnetronix, Inc. All rights reserved.